Clinical characteristics and management of iron overload in 631 patients with chronic transfusion dependency: Results from a multicentre, observational study

Blood Transfusion

Volumn 12, Issue SUPPL.1, 2014, Pages

  Cid, Joan ^a   Palomera, Luis ^b   Diaz, Matias ^c   Zamora, Concha ^d   Solano, Fernando ^e  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^c HOSPITAL SON DURETA   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL NUESTRA SEÑORA DEL PRADO   (Spain)

Author keywords

Chelation therapy; Iron overload; Observational study; Transfusion dependency

Indexed keywords

AGED; BENZOATES; BLOOD TRANSFUSION; CHELATION THERAPY; COMORBIDITY; DISEASE MANAGEMENT; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; GUIDELINE ADHERENCE; HEMATOLOGIC DISEASES; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; SPAIN; TRIAZOLES;

EID: 84893922594     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.0173-12     Document Type: Article

References (26)

1. Malcovati L, Della Porta MG, Strupp C, et al. Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica 2011; 96: 1433-40.
2. Tefferi A, Siragusa S, Hussein K, et al. Transfusiondependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis-prognostic relevance is independent of IPSS or karyotype. Am J Hematol 2010; 85: 14-7.
3. Cermak J, Kacirkova P, Mikulenkova D, et al. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess of blasts. Leuk Res 2009; 33: 1469-74.
4. Elena C, Passamonti F, Rumi E, et al. Red blood cell transfusion- dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. Haematologica 2011; 96: 167-70.
5. Gale RP, Barosi G, Barbui T et al. What are RBC-transfusiondependence and -independence? Leuk Res 2011; 35: 8-11.
6. Ozment CP, Turi JL. Iron overload following red blood cell transfusion and its impact on disease severity. Biochim Biophys Acta 2009; 1790: 694-701.
7. de Sousa M. Immune cell functions in iron overload. Clin Exp Immunol 1989; 75: 1-6.
8. Altés A, Ruiz MA, Castell C, et al. Iron deficiency and iron overload in an adult population in Catalonia. Med Clin (Barc) 2004; 123: 131-3.
9. del Castillo Rueda A, Ravell Aumaitre JC, Khosravi Shahi P et al. Iron overcharge in myelodysplasic syndromes and iron chelation therapy. An Med Interna 2007; 24: 565-6.
10. Malcovati L, Porta MG, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol 2005; 23: 7594-603.
11. Malcovati L. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res 2007; 31 (Suppl.3): S2-6.
12. Ault P, Jones K. Understanding iron overload: screening, monitoring, and caring for patients with transfusion-dependent anemias. Clin J Oncol Nurs 2009; 13: 511-7.
13. Borgna-Pignatti C, Castriota-Scanderbeg A. Methods for evaluating iron stores and efficacy of chelation in transfusional hemosiderosis. Haematologica 1991; 76: 409-13.
14. Spanish Group for Myelodysplastic Syndromes (GESMD), Spanish Society of Haematology and Haemotherapy (SEHH). Spanish guidelines for the diagnosis and treatment of myelodysplastic syndromes and chronic myelomonocytic leukaemia. Haematologica 2012; 97 (Suppl.
15. Araújo A, Drelichman G, Cançado RD, et al. Management of transfusional iron overload in Latin America: current outlook and expert panel recommendations. Hematology 2009; 14: 22-32.
16. Vlachos A, Ball S, Dahl N, et al. Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference. Br J Haematol 2008; 142: 859-76.
17. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008; 83: 858-61.
18. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res 2007; 31 (Suppl.3): S10-5.
19. Angelucci E, Barosi G, Camaschella C, et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93: 741-52.
20. Porter JB. Practical management of iron overload. Br J Haematol 2001; 115: 239-52.
21. Arrizabalaga B, Cañizo MC, Remacha A, et al. Guía Clínica de Quelación del Paciente con Síndrome Mielodisplásico. Haematologica 2008; 93: 1-12.
22. Santini V, Alessandrino PE, Angelucci E, et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010; 34: 1576-88.
23. Sanz GF, Sanz MA, Vallespi T, et al. Two regression models and a scoring system for predicting survival and planning treatment in myelodysplastic syndromes: a multivariate analysis of prognostic factors in 370 patients. Blood 1989; 74: 395-408.
24. Jacobs A, Miller F, Worwood M, et al. Ferritin in the serum of normal subjects and patients with iron deficiency and iron overload. BMJ 1972; 4: 206-8.
25. Fung EB, Harmatz PR, Milet M, et al. Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions. Transfusion 2008; 48: 1971-80.
26. Remacha A, Sanz C, Contreras E, et al. Guidelines on haemovigilance of post-transfusional iron overload. Blood Transfus 2013: 11: 128-39.